Pazufloxacin Mesylate for Injection

1. This product is a new type of fluoroquinolone antibacterial drug. Its main mechanism of action is to inhibit the activity of bacterial DNA helicase enzyme topoisomerase IV and hinder the replication of bacterial DNA to achieve antibacterial effect. 2. Pazufloxacin is effective against aerobic bacteria, general anaerobic bacteria, and anaerobic Gram-positive bacteria and Gram-negative bacteria. It has the same antibacterial effect as imipenem and ciprofloxacin, and its antibacterial spectrum is the same as ceftazidime and gentamicin. It has strong antibacterial activity against clinically isolated Staphylococcus, Enterobacter, Pseudomonas aeruginosa, various Gram-negative bacteria, Pseudomonas and Prevotella bacteria. This product has strong antibacterial activity against resistant bacteria to imipenem, cefazolin, ceftazidime, intestinal bacterial flora, ampicillin-resistant bacteria - Haemophilus influenzae, resistant bacteria produced by imipenem, gentamicin, Pseudomonas aeruginosa when used alone or in combination with ceftazidime, and β-lactamase hydrolysis of imipenem to produce resistant bacteria - Serratia marcescens. 3. Antibacterial effect This product has a killing effect on Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus. This product has a strong killing effect on Pseudomonas aeruginosa in the stationary phase, logarithmic growth phase, and stable phase, and the intensity of action is stronger than ceftazidime and gentamicin. The antibacterial effect of this product on Staphylococcus aureus in the stable phase is the same as that of ceftazidime and gentamicin, and the killing effect on Staphylococcus aureus in the stationary phase and growth phase is stronger than that of ceftazidime.

Active ingredient: Pazufloxacin mesylate

White to light yellow crystalline powder, odorless and bitter.

This product is suitable for the following infections caused by sensitive bacteria: 1. Secondary infections of chronic respiratory diseases, such as chronic bronchitis, diffuse bronchiolitis, bronchiectasis, emphysema, pulmonary interstitial fibrosis, bronchial asthma, old pulmonary tuberculosis, pneumonia, lung abscess; 2. Pyelonephritis, complicated cystitis, prostatitis; 3. Burn wound infection, surgical wound infection; 4. Cholecystitis, cholangitis, liver abscess; 5. Intra-abdominal abscess, peritonitis; 6. Reproductive organ infection, such as adnexitis, endometritis, pelvic inflammatory disease.

Usage: Dissolve 0.3g of this product in 100ml 0.9% sodium chloride injection and drip intravenously. Dosage: 0.3g once, twice a day, intravenous drip time is 30-60 minutes, and the course of treatment is 7-14 days. The dosage can be adjusted according to the patient's age and condition.

The main clinical adverse reactions of this product are diarrhea, rash, nausea, and vomiting. Laboratory tests show elevated ALT, AST, ALP, r-GTP, and increased eosinophils. (1) Clinical adverse reactions: 1) Acute renal failure: May cause acute renal failure. 2) Abnormal liver function, jaundice. 3) Pseudomembranous colitis: Severe enteritis accompanied by bloody stools may occur. If abdominal pain or frequent diarrhea occurs, the drug should be discontinued immediately and appropriate preventive measures should be taken. 4) Granulocytopenia, thrombocytopenia. 5) Rhabdomyolysis: If myalgia, weakness, elevated creatine phosphokinase (CPK), or elevated myosin in the blood or urine occurs, the drug should be discontinued immediately. Rhabdomyolysis can also lead to acute renal failure. 6) Spasms. 7) Shock, over-exertion

Patients with a history of allergy to pazufloxacin and quinolones are contraindicated.

Not yet clear

Keep away from light, tightly closed, in a cool place.

0.5g (based on C16H15FN2O4)

Jiangsu Kanion Pharmaceutical Co., Ltd.

• Founded in:

  1996-05-08

• Address:

  Lianyungang Economic and Technological Development Zone Jiangning Industrial City

• Tax NO.:

  91320700138997640W

• Registered Funds:

  581.797452 million yuan

• Website:

  Log in to view

• Email:

  Log in to view